Ciclesonide

Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco[1] for hay fever in the US and Canada.

Ciclesonide
Clinical data
Other names(11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
AHFS/Drugs.comMonograph
MedlinePlusa607008
Pregnancy
category
  • AU: B3
Routes of
administration		Nasal inhalation
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.908
Chemical and physical data
FormulaC32H44O7
Molar mass540.697 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[2]

It was patented in 1990 and approved for medical use in 2005.[3] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[4]

See also

References
  1. "Covis Pharma – Products".
  2. Mutch E, Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–64. doi:10.1016/j.bcp.2007.01.031. PMID 17331475.
  3. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.
  4. "FDA News Release. FDA Approves New Treatment for Allergies". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30.

Further reading
  • Rossi S, ed. (2006). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.